Spontaneous glutamate release activates mGluR signaling to drive rapid antidepressant responses
Proceedings of the National Academy of Sciences · 16.09.2025 · 122 (37)
DOI: 10.1073/pnas.2510642122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 09.09.2025. Verfasst von Clara I McCarthy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37240. Hauptthemen laut MEDLINE: Glutamic Acid, Receptor, Metabotropic Glutamate 5, Antidepressive Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIMH NIH HHS, HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS), NICHD NIH HHS.
Abstract (Originalsprache)
Major depressive disorder affects millions worldwide, yet current treatments require prolonged administration. In contrast, ketamine produces rapid antidepressant effects by blocking spontaneous N-Methyl-D-Aspartate (NMDA) receptor signaling, which lifts the suppression of protein synthesis and triggers homeostatic synaptic plasticity. Here, we identify a parallel signaling pathway involving metabotropic glutamate receptor 5 (mGluR5) that promotes rapid antidepressant-like effects. We show that enhancing the endogenous mGluR5 signaling produces synaptic potentiation in the hippocampus and triggers the rapid antidepressant effect, similar to ketamine. Importantly, blocking mGluR5 prevents ketamine’s effects, revealing a synergy between the two pathways. At the cellular level, spontaneous calcium transients mediated by mGluR5 activate the phosphatase calcineurin and promote eukaryotic elongation factor 2 (eEF2) dephosphorylation, increasing BDNF translation to drive synaptic plasticity. We show that quantal glutamate release activates two spatially segregated Ca 2+ signals—NMDAR- and mGluR5-driven—which exert opposing effects on protein synthesis. Together, these findings highlight mGluR5 as a promising therapeutic target for rapid antidepressant action, harnessing the complex nanoscale organization of synapses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37240.
- Department of Pharmacology, Vanderbilt University, Nashville, TN 37240.
ORCID-Profile: Clara I McCarthy, Z Zack Ma, Lisa M Monteggia, Ege T Kavalali
Förderung
- NIMH NIH HHS
- HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- NICHD NIH HHS
- NINDS NIH HHS
- Brain and Behavior Research Foundation (BBRF)
- HHS | NIH | National Institute of Mental Health (NIMH)
Zitieren
APA
McCarthy, C. I., Zack Ma, Z., Monteggia, L. M., & Kavalali, E. T. (2025). Spontaneous glutamate release activates mGluR signaling to drive rapid antidepressant responses. Proceedings of the National Academy of Sciences, 122(37). https://doi.org/10.1073/pnas.2510642122
Vancouver
McCarthy CI, Zack Ma Z, Monteggia LM, Kavalali ET. Spontaneous glutamate release activates mGluR signaling to drive rapid antidepressant responses. Proceedings of the National Academy of Sciences. 2025;122(37). doi:10.1073/pnas.2510642122
BibTeX
@article{McCarthy2025,
author = {McCarthy, Clara I and Zack Ma, Z and Monteggia, Lisa M and Kavalali, Ege T},
title = {Spontaneous glutamate release activates mGluR signaling to drive rapid antidepressant responses},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {37},
doi = {10.1073/pnas.2510642122}
}
EUVIMED